Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Glioma 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancies 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Cholangiocarcinoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 45Radiotherapy 17Magnetic Resonance Spectroscopy 17Specimen Handling 14Bevacizumab 12pembrolizumab 11Lomustine 9Radiation 8fludarabine 7Cyclophosphamide 7atezolizumab 4Biopsy 4olaparib 3Transurethral Resection of Bladder 3Surgical Procedures, Operative 3Nivolumab 3Leukapheresis 3D2C7-(scdsFv)-PE38KDEL 3Blood Specimen Collection 3Aminolevulinic Acid 3regorafenib 2fluciclovine F-18 2contrast agent BR1 2antisecretory factor 2abemaciclib 2Restraint, Physical 2Re-Irradiation 2Radiation Dose Hypofractionation 2Palliative Care 2Oncolytic Virotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Glioblastoma × olutasidenib × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡